Logo image of AMS

AMERICAN SHARED HOSPITAL SER (AMS) Stock Fundamental Analysis

NYSEARCA:AMS - NYSE Arca - US0295951059 - Common Stock - Currency: USD

2.7475  -0.01 (-0.45%)

Fundamental Rating

5

Taking everything into account, AMS scores 5 out of 10 in our fundamental rating. AMS was compared to 107 industry peers in the Health Care Providers & Services industry. AMS has a medium profitability rating, but doesn't score so well on its financial health evaluation. AMS is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

AMS had positive earnings in the past year.
AMS had a negative operating cash flow in the past year.
Of the past 5 years AMS 4 years were profitable.
In the past 5 years AMS always reported a positive cash flow from operatings.
AMS Yearly Net Income VS EBIT VS OCF VS FCFAMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M

1.2 Ratios

The Return On Assets of AMS (6.21%) is better than 87.04% of its industry peers.
AMS has a Return On Equity of 14.87%. This is amongst the best in the industry. AMS outperforms 83.33% of its industry peers.
AMS has a Return On Invested Capital of 2.11%. This is comparable to the rest of the industry: AMS outperforms 45.37% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMS is below the industry average of 8.16%.
Industry RankSector Rank
ROA 6.21%
ROE 14.87%
ROIC 2.11%
ROA(3y)1.57%
ROA(5y)-2.05%
ROE(3y)3.27%
ROE(5y)-4.86%
ROIC(3y)5.2%
ROIC(5y)N/A
AMS Yearly ROA, ROE, ROICAMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10 -20 -30

1.3 Margins

AMS's Profit Margin of 15.74% is amongst the best of the industry. AMS outperforms 98.15% of its industry peers.
AMS's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 5.36%, AMS is in the better half of the industry, outperforming 64.81% of the companies in the same industry.
In the last couple of years the Operating Margin of AMS has declined.
Looking at the Gross Margin, with a value of 35.23%, AMS is in the better half of the industry, outperforming 62.96% of the companies in the same industry.
In the last couple of years the Gross Margin of AMS has grown nicely.
Industry RankSector Rank
OM 5.36%
PM (TTM) 15.74%
GM 35.23%
OM growth 3YN/A
OM growth 5Y-9.27%
PM growth 3YN/A
PM growth 5Y-11.18%
GM growth 3Y20.48%
GM growth 5Y2.89%
AMS Yearly Profit, Operating, Gross MarginsAMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

2

2. Health

2.1 Basic Checks

AMS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for AMS has been increased compared to 1 year ago.
The number of shares outstanding for AMS has been increased compared to 5 years ago.
AMS has a worse debt/assets ratio than last year.
AMS Yearly Shares OutstandingAMS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
AMS Yearly Total Debt VS Total AssetsAMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 1.06, we must say that AMS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.06, AMS is doing worse than 64.81% of the companies in the same industry.
AMS has a Debt/Equity ratio of 0.58. This is a neutral value indicating AMS is somewhat dependend on debt financing.
AMS has a Debt to Equity ratio (0.58) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z 1.06
ROIC/WACC0.24
WACC8.62%
AMS Yearly LT Debt VS Equity VS FCFAMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M 15M 20M 25M

2.3 Liquidity

A Current Ratio of 1.46 indicates that AMS should not have too much problems paying its short term obligations.
The Current ratio of AMS (1.46) is comparable to the rest of the industry.
AMS has a Quick Ratio of 1.46. This is a normal value and indicates that AMS is financially healthy and should not expect problems in meeting its short term obligations.
AMS has a Quick ratio (1.46) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 1.46
AMS Yearly Current Assets VS Current LiabilitesAMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 752.43% over the past year.
Measured over the past years, AMS shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.91% on average per year.
AMS shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.80%.
The Revenue has been growing slightly by 1.59% on average over the past years.
EPS 1Y (TTM)752.43%
EPS 3YN/A
EPS 5Y-10.91%
EPS Q2Q%-250%
Revenue 1Y (TTM)20.8%
Revenue growth 3Y6.13%
Revenue growth 5Y1.59%
Sales Q2Q%36.43%

3.2 Future

Based on estimates for the next years, AMS will show a very strong growth in Earnings Per Share. The EPS will grow by 144.95% on average per year.
AMS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.52% yearly.
EPS Next Y940%
EPS Next 2Y144.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.6%
Revenue Next 2Y23.52%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AMS Yearly Revenue VS EstimatesAMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
AMS Yearly EPS VS EstimatesAMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.1 0.2 0.3 0.4 0.5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 68.69, which means the current valuation is very expensive for AMS.
AMS's Price/Earnings is on the same level as the industry average.
AMS is valuated expensively when we compare the Price/Earnings ratio to 29.35, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 9.07, the valuation of AMS can be described as very reasonable.
AMS's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMS is cheaper than 91.67% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AMS to the average of the S&P500 Index (22.10), we can say AMS is valued rather cheaply.
Industry RankSector Rank
PE 68.69
Fwd PE 9.07
AMS Price Earnings VS Forward Price EarningsAMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMS indicates a rather cheap valuation: AMS is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.55
AMS Per share dataAMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

AMS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of AMS may justify a higher PE ratio.
AMS's earnings are expected to grow with 144.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y144.95%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMERICAN SHARED HOSPITAL SER

NYSEARCA:AMS (3/7/2025, 8:04:53 PM)

2.7475

-0.01 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners16.56%
Inst Owner Change-1.6%
Ins Owners30.23%
Ins Owner Change2.11%
Market Cap17.64M
Analysts80
Price Target4.95 (80.16%)
Short Float %0.76%
Short Ratio2.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-125.64%
Min EPS beat(2)-137.13%
Max EPS beat(2)-114.14%
EPS beat(4)1
Avg EPS beat(4)-22.06%
Min EPS beat(4)-137.13%
Max EPS beat(4)197.03%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.81%
Min Revenue beat(2)-7.97%
Max Revenue beat(2)13.59%
Revenue beat(4)3
Avg Revenue beat(4)4.35%
Min Revenue beat(4)-7.97%
Max Revenue beat(4)13.59%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.78%
PT rev (3m)7.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-28.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.28%
Valuation
Industry RankSector Rank
PE 68.69
Fwd PE 9.07
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.7
EV/EBITDA 2.55
EPS(TTM)0.04
EY1.46%
EPS(NY)0.3
Fwd EY11.03%
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS3.89
BVpS4.12
TBVpS3.91
PEG (NY)0.07
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.21%
ROE 14.87%
ROCE 2.93%
ROIC 2.11%
ROICexc 2.91%
ROICexgc 3.02%
OM 5.36%
PM (TTM) 15.74%
GM 35.23%
FCFM N/A
ROA(3y)1.57%
ROA(5y)-2.05%
ROE(3y)3.27%
ROE(5y)-4.86%
ROIC(3y)5.2%
ROIC(5y)N/A
ROICexc(3y)7.41%
ROICexc(5y)N/A
ROICexgc(3y)7.79%
ROICexgc(5y)N/A
ROCE(3y)6.71%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y4.52%
ROICexc growth 3YN/A
ROICexc growth 5Y3.43%
OM growth 3YN/A
OM growth 5Y-9.27%
PM growth 3YN/A
PM growth 5Y-11.18%
GM growth 3Y20.48%
GM growth 5Y2.89%
F-Score3
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA 2.15
Cap/Depr 58.16%
Cap/Sales 13.5%
Interest Coverage 1.05
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.46
Quick Ratio 1.46
Altman-Z 1.06
F-Score3
WACC8.62%
ROIC/WACC0.24
Cap/Depr(3y)54.4%
Cap/Depr(5y)36.63%
Cap/Sales(3y)13.62%
Cap/Sales(5y)9.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)752.43%
EPS 3YN/A
EPS 5Y-10.91%
EPS Q2Q%-250%
EPS Next Y940%
EPS Next 2Y144.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)20.8%
Revenue growth 3Y6.13%
Revenue growth 5Y1.59%
Sales Q2Q%36.43%
Revenue Next Year29.6%
Revenue Next 2Y23.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.84%
EBIT growth 3YN/A
EBIT growth 5Y-7.83%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-191.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-136.18%
OCF growth 3Y-16.3%
OCF growth 5Y-6.64%